Alopecia areata is an autoimmune condition that causes sudden, often patchy hair loss and can have a significant impact on your confidence and emotional wellbeing. If you have moderate-to-severe alopecia areata, you may find that traditional treatments, such as corticosteroids or topical immunotherapies, do not always provide the results you are hoping for.
The THRIVE-AA Phase III trials investigated ritlecitinib, a selective JAK3/TEC kinase inhibitor, as a targeted oral treatment for adults with severe alopecia areata. These studies evaluated how well the medicine promoted hair regrowth while also assessing its safety and long-term effectiveness.
Understanding the design and findings of the THRIVE-AA trials can help you better understand where ritlecitinib fits into modern alopecia areata treatment. The results have expanded the evidence for targeted therapies and provided you and your clinician with another important treatment option for managing moderate-to-severe alopecia areata.
What Ritlecitinib Is
Ritlecitinib is an oral small-molecule medicine that selectively targets Janus kinase 3 (JAK3) and TEC family kinases. If you have moderate-to-severe alopecia areata, this treatment is designed to target the immune processes that contribute to your hair loss rather than simply treating the visible patches. This means you are receiving a therapy that focuses on the underlying cause of the condition.
By modifying the immune pathways involved in alopecia areata, ritlecitinib helps reduce the autoimmune attack on your hair follicles. By modifying immune pathways involved in alopecia areata, ritlecitinib may help create conditions that support hair regrowth in some patients. Although results vary, you may notice improvements as treatment continues.
Because ritlecitinib selectively targets JAK3 and TEC family kinases, it is designed to have a more focused effect than broader JAK inhibitors. This targeted approach is designed to selectively affect specific immune pathways, although the overall safety profile still requires careful monitoring.
Rationale for the THRIVE-AA Trials
The THRIVE-AA trials were designed to evaluate whether ritlecitinib could restore hair growth in adults with severe alopecia areata. If you are considering this treatment, understanding the purpose of these studies can help you appreciate why ritlecitinib has become an important addition to modern alopecia areata management. The trials were developed to answer the key questions that matter most to you and your clinician.
The researchers aimed to generate high-quality evidence on how effective ritlecitinib was, how safe it was to use and whether its benefits could be maintained over the long term. If you are thinking about starting treatment, this information helps you understand both the potential benefits and the possible risks before making a decision.
By conducting parallel Phase III studies, the researchers were able to confirm that the findings were consistent across different groups of participants. This gives you greater confidence that the results are reliable and supports the use of ritlecitinib as an evidence-based treatment option for severe alopecia areata.
Study Design
The THRIVE-AA programme consisted of randomised, double-blind, placebo-controlled Phase III clinical trials designed to evaluate the effectiveness and safety of ritlecitinib in adults with severe alopecia areata. If you are looking at the evidence behind this treatment, this type of study design provides a high level of confidence in the results. It also helps you understand how the treatment performs under carefully controlled conditions.
To take part in the trials, participants had to have at least 50% scalp hair loss, ensuring the studies focused on people with clinically significant alopecia areata. If you have extensive hair loss, the participants included in these trials are likely to be more representative of your condition and treatment needs.
The primary and secondary endpoints assessed how well ritlecitinib promoted hair regrowth, how safe it was to use and how treatment affected participants’ quality of life. This gave you a broader picture of the treatment’s overall benefits, beyond simply measuring changes in scalp hair.
Patient Population
The THRIVE-AA trials enrolled adults with severe alopecia areata affecting the scalp and, in many cases, the eyebrows, eyelashes or other areas of body hair. If you have extensive hair loss, the participants in these studies may better reflect the type of alopecia areata you are experiencing. This makes the findings more relevant when you are considering treatment options.
Many participants had been living with alopecia areata for several years and had already tried other treatments with limited success. If you have found that previous therapies have not provided the results you hoped for, the trial outcomes may be particularly meaningful because they included people with similar treatment histories.
The studies also included participants from a range of demographic backgrounds, helping researchers evaluate ritlecitinib across a broad patient population. This gives you greater confidence that the findings are more likely to apply to people with different backgrounds and varying patterns of alopecia areata.
Dosing Regimens
In the THRIVE-AA trials, ritlecitinib was taken as an oral tablet once a day using pre-specified dosing regimens. If you are considering treatment, a once-daily tablet may be easier to fit into your daily routine than therapies that require regular injections or frequent applications. This simple dosing schedule can make long-term treatment more practical.
The convenience of oral treatment may also help you stay consistent with your medication, which is important when managing a long-term condition such as alopecia areata. Taking your treatment as prescribed gives you the best opportunity to achieve and maintain hair regrowth over time.
The doses used in the studies were selected to balance effectiveness with tolerability. If you are prescribed ritlecitinib, your clinician will recommend the most appropriate treatment approach for your individual needs while monitoring your response and overall health throughout therapy.
Primary Endpoint
The primary endpoint of the THRIVE-AA trials measured how many participants achieved substantial scalp hair regrowth after 24 weeks of treatment. If you are reading the study results, you will see that this was assessed using the Severity of Alopecia Tool (SALT) score, which is the standard method used to measure the extent of scalp hair loss in clinical trials.
Achieving this endpoint represented a clinically meaningful improvement because it reflected a significant restoration of scalp hair coverage. If you have moderate-to-severe alopecia areata, this level of regrowth may have a positive impact on both your appearance and your confidence.
The researchers compared the results in participants receiving ritlecitinib with those receiving a placebo. This comparison helped you see whether the improvements were genuinely due to the treatment rather than changes that might have occurred without active therapy.
Secondary Endpoints
The THRIVE-AA trials also assessed several secondary endpoints to provide a wider understanding of how ritlecitinib affected people with severe alopecia areata. If you have hair loss affecting areas beyond your scalp, these additional results can help you understand the potential benefits of treatment.
Researchers looked at improvements in eyebrow, eyelash and body hair coverage, alongside patient-reported outcomes that measured quality of life, confidence and daily functioning. If alopecia areata has affected how you feel about your appearance or your everyday activities, these outcomes show the importance of measuring more than just hair regrowth.
Safety and tolerability were also key parts of the secondary analyses. This helps you and your clinician consider not only how effective ritlecitinib may be, but also how suitable and manageable it is as part of your long-term treatment plan.
Efficacy Outcomes
The THRIVE-AA trials showed that ritlecitinib achieved significantly higher rates of hair regrowth compared with placebo in adults with severe alopecia areata. If you are considering this treatment, these findings provide important evidence that ritlecitinib can help support meaningful hair recovery in people with extensive hair loss.
Many participants experienced noticeable improvements in scalp hair coverage, as well as regrowth in areas such as the eyebrows and eyelashes. If you have lost hair in multiple areas, these results may be particularly relevant because they show that treatment benefits can extend beyond the scalp.
Overall, the findings suggest that ritlecitinib has a broad effect across different hair-bearing regions affected by alopecia areata. This gives you a clearer understanding of why the THRIVE-AA trials are considered an important step forward in developing targeted treatments for this condition.
Onset of Effect
Some patients receiving ritlecitinib may begin to see early signs of improvement within the first few months, although the timing and extent of regrowth vary between individuals. If you are considering this treatment, seeing early signs of improvement can help you understand what you may expect during the initial stages of therapy.
Early changes in hair growth can improve treatment satisfaction and encourage you to continue following your prescribed treatment plan. When you see progress, you may feel more confident that the therapy is working, even though further regrowth may continue gradually over time.
A faster response can be especially meaningful in alopecia areata because hair loss can affect your appearance, confidence and emotional wellbeing. For many people, early improvement provides reassurance and can have a positive impact on their overall treatment experience.
Quality of Life Benefits
The THRIVE-AA trials showed that the benefits of ritlecitinib extended beyond physical hair regrowth. If you are living with alopecia areata, you may understand how hair loss can affect your confidence, social interactions and emotional wellbeing.
Participants reported improvements in self-esteem and social confidence as their hair coverage improved. If you have experienced embarrassment, stress or reduced confidence because of visible hair loss, these findings highlight how effective treatment can positively influence your daily life.
The reduction in hair loss was linked with meaningful improvements in quality of life, showing that clinical results can translate into real-world benefits. This helps you see why measuring patient experiences is just as important as measuring changes in hair growth during clinical trials.
Comparison Between Doses
The THRIVE-AA trials showed that higher doses of ritlecitinib generally provided greater treatment benefits, although both dose groups performed better than placebo. If you are discussing treatment options with your clinician, these findings can help you understand why different dosing approaches may be considered.
The most suitable dose depends on factors such as the severity of your alopecia areata, your overall health and how well you tolerate treatment. Your clinician will consider your individual circumstances to choose a treatment approach that offers the best balance between effectiveness and safety.
This personalised dosing strategy allows treatment to be adjusted to your specific needs. By tailoring therapy, you and your clinician can work towards achieving the best possible hair regrowth outcomes while managing any potential side effects.
Long-Term Efficacy
Follow-up data from the THRIVE-AA trials showed that many participants maintained hair regrowth over 48 weeks of treatment. If you are considering ritlecitinib, these longer-term results can help you understand its potential role as an ongoing treatment option for severe alopecia areata.
Maintaining hair regrowth over time is an important goal because alopecia areata is a chronic autoimmune condition that can relapse. Continuing therapy as advised by your clinician may help maintain treatment benefits in some patients.
Consistency plays an important role in long-term management. By following your treatment plan and attending regular reviews, you can allow your clinician to monitor your progress, manage any concerns and support the best possible long-term outcome.
Safety Profile
The THRIVE-AA trials showed that ritlecitinib was generally well tolerated among adults with severe alopecia areata. If you are considering this treatment, understanding its safety profile can help you weigh the potential benefits alongside any possible risks.
Most reported side effects were mild to moderate in severity, with common events including nasopharyngitis (cold-like symptoms) and headache. While these effects may not occur in everyone, you should discuss any new or persistent symptoms with your clinician during treatment.
Serious adverse events were uncommon in the clinical trials, supporting the overall favourable safety profile of ritlecitinib. With regular monitoring and follow-up, you and your clinician can make informed decisions about whether this treatment remains the right option for you.
Laboratory Monitoring
Routine laboratory monitoring is recommended while you are taking ritlecitinib to help ensure treatment remains safe over time. These checks allow your clinician to monitor important markers, including blood counts and liver function, and identify any changes that may need attention.
Because ritlecitinib selectively targets JAK3 and TEC family kinases, its more focused mechanism may offer a different safety profile compared with broader immunosuppressive treatments. If you are using long-term therapy, your clinician will still review your results regularly to make sure the treatment continues to be appropriate for you.
Regular monitoring is an important part of maintaining safe and effective treatment. By attending your follow-up appointments and completing recommended tests, you can help your clinician identify any concerns early and continue your care with confidence.
Infection Risk
The THRIVE-AA trials found that mild infections occurred in some participants taking ritlecitinib, but these were generally manageable. If you are considering this treatment, it can be reassuring to know that most reported infections were not severe and did not prevent participants from continuing therapy.
The studies did not show a significant increase in opportunistic infections compared with placebo. This provides useful information if you are concerned about how a targeted immune treatment may affect your ability to fight infections.
Although ritlecitinib works by modifying immune pathways involved in alopecia areata, regular monitoring remains important. By keeping in contact with your clinician and reporting any symptoms early, you can help ensure your treatment remains safe and well managed.
Cardiovascular and Thrombotic Considerations
The THRIVE-AA trials did not show a higher rate of major cardiovascular or thrombotic events with ritlecitinib compared with placebo. If you are considering this treatment, these findings provide reassuring information about its cardiovascular safety within the clinical trial population.
However, if you have existing cardiovascular risk factors, your clinician will consider your individual health profile before starting therapy. Factors such as your medical history and any other conditions you may have can help guide whether ritlecitinib is a suitable option for you.
Overall, the safety data support the use of ritlecitinib in carefully selected patients with appropriate monitoring. By discussing your health history openly with your clinician, you can make a more informed decision about whether this treatment aligns with your needs.
Treatment Discontinuation
The THRIVE-AA trials showed that few participants stopped taking ritlecitinib because of adverse events. If you are considering a long-term oral treatment for alopecia areata, these findings suggest that many people were able to continue therapy with good overall tolerability.
Most participants tolerated ritlecitinib well throughout the study period, allowing researchers to assess both its effectiveness and safety over time. If you start treatment, your clinician will continue to monitor your response and discuss any side effects you may experience.
These results support the use of ritlecitinib as a practical long-term oral therapy for severe alopecia areata. With regular follow-up and appropriate monitoring, you can work with your clinician to maintain a treatment approach that supports your hair regrowth goals.
Integration With Other Therapies
In some cases, dermatologists may consider additional treatments alongside ritlecitinib, depending on individual circumstances and clinical judgement. If you are receiving this therapy, your clinician may consider combining it with topical treatments or supportive care to help optimise your overall results.
Additional therapies may support areas where you want further improvement, such as scalp, eyebrow or eyelash regrowth. If you are using more than one treatment, your clinician can help you understand how each option contributes to your individual care plan and what results you can realistically expect.
Combination strategies should always be guided by a specialist who understands your condition and treatment history. By tailoring your approach, you and your clinician can aim to improve hair regrowth outcomes while ensuring that your treatment remains safe and appropriate for your needs.
Patient Education
Understanding what to expect from ritlecitinib can help you feel more confident about your treatment journey. Before starting therapy, your clinician should explain how long hair regrowth may take, the possible side effects you may experience and why regular laboratory monitoring is recommended.
Setting realistic expectations is important because hair regrowth is usually gradual rather than immediate. If you understand the expected timeline and treatment process, you may feel more prepared to continue your therapy consistently and recognise the progress you are making.
Good patient education also helps you make informed decisions about your care. When you understand the potential benefits, risks and monitoring requirements, you can work together with your clinician to choose a treatment approach that best matches your goals and needs.
Psychological Support
Hair loss from alopecia areata can affect much more than your appearance. If you are living with the condition, you may experience changes in your confidence, self-esteem and willingness to take part in social activities.
Medical treatment such as ritlecitinib can help address hair regrowth, but emotional support can also play an important role in your overall care. You may benefit from counselling, talking therapies or peer support groups where you can connect with others who understand the challenges of living with hair loss.
A holistic approach considers both your physical symptoms and emotional wellbeing. By addressing the psychological impact alongside medical treatment, you and your healthcare team can create a more complete care plan that supports your quality of life.
Long-Term Management Strategy
Alopecia areata is a long-term autoimmune condition that often requires ongoing management to maintain hair regrowth and reduce the risk of relapse. If you have responded well to ritlecitinib, continuing treatment as advised by your clinician may help you preserve the improvements you have achieved.
Regular follow-up appointments, maintenance therapy and healthy lifestyle habits all play an important role in supporting long-term outcomes. Your clinician will monitor your progress, review your response to treatment and make adjustments if needed to ensure your care remains suitable for you.
Starting appropriate treatment early and staying consistent with your management plan can help maximise your chances of achieving better results. By working closely with your healthcare team, you can take an active role in managing alopecia areata over the long term.
Special Populations
The THRIVE-AA trials provided important evidence in adults with severe alopecia areata, but further research is needed to understand how ritlecitinib performs in groups such as adolescents, older adults and people with additional health conditions. If you fall into one of these groups, your clinician may consider the available evidence alongside your individual circumstances before recommending treatment.
Personalised dosing and careful monitoring are especially important when you have other medical considerations. Your clinician will review factors such as your age, overall health, existing conditions and any other medicines you take to ensure that treatment decisions are appropriate for you.
As more real-world evidence becomes available, it will continue to shape clinical guidance and improve understanding of how ritlecitinib can be used in different patient populations. This ongoing research will help you and your clinician make more informed decisions about long-term alopecia areata management.
Cost and Access Considerations
Ritlecitinib is a newer treatment option for alopecia areata, so access may depend on factors such as cost, healthcare availability and insurance coverage. If you are considering this therapy, discussing these practical aspects with your clinician can help you understand whether it is a realistic option for your situation.
Your clinician can explain the expected costs, availability and any local prescribing requirements that may affect access to treatment. If affordability is a concern, you can have an open conversation about alternative approaches or support options that may be available to you.
Patient assistance programmes and other support schemes may help improve access for eligible individuals. By discussing both medical and practical considerations, you and your clinician can choose a treatment plan that aligns with your needs and circumstances.
Rapid Improvement and Satisfaction
Early signs of hair regrowth can have a positive effect on how you experience treatment with ritlecitinib. If you begin to notice improvements in the first few months, it may increase your confidence in the therapy and help you feel more encouraged about your progress.
Seeing visible changes can also improve treatment satisfaction and make it easier for you to stay consistent with your medication plan. When you feel that treatment is making a difference, you may be more likely to continue regular follow-up and remain engaged with your long-term care.
A faster response is particularly meaningful in alopecia areata because hair loss can affect your appearance, confidence and quality of life. By helping you see progress sooner, effective treatment can provide reassurance and support a more positive treatment experience.
Shared Decision-Making
Shared decision-making plays an important role in choosing the right treatment approach for alopecia areata. If you are considering ritlecitinib, having an open discussion with your clinician can help you understand your options and feel more confident about the decisions you make.
Talking through the potential benefits, possible risks and realistic expectations allows your treatment plan to reflect your personal goals. When you understand how the therapy works and what results you may achieve, you are more likely to stay engaged with your treatment and follow your care plan consistently.
This approach is especially important for chronic visible conditions such as alopecia areata, where treatment can affect both your appearance and emotional wellbeing. By working together, you and your clinician can create a personalised plan that supports your long-term needs and priorities.
Real-World Applicability
The THRIVE-AA trials provide strong evidence supporting the use of ritlecitinib in clinical practice, although individual responses can vary. If you are considering this treatment, it is important to remember that your results may not be exactly the same as those seen in clinical studies.
Your clinician will tailor treatment based on factors such as the severity of your alopecia areata, your previous therapies, your overall health and your personal treatment goals. This personalised approach helps you receive care that is suited to your specific needs while maintaining appropriate safety monitoring.
As more real-world data becomes available, it will continue to improve understanding of how ritlecitinib performs outside clinical trials. These insights will help you and your clinician make more informed decisions about long-term treatment strategies for alopecia areata.
Implications for Clinical Practice
The THRIVE-AA trials have shown that ritlecitinib provides an effective oral treatment option for adults with severe alopecia areata. If you have extensive hair loss, this type of targeted tablet therapy may offer an alternative when topical treatments or injections have not provided the improvement you were looking for.
Ritlecitinib may be suitable if you have not responded well to previous treatments or if you need a more targeted approach to managing your condition. Your clinician will consider factors such as the severity of your alopecia areata, your previous treatment history and your overall health before recommending whether it is appropriate for you.
In clinical practice, ritlecitinib is integrated into a personalised treatment plan rather than used as a one-size-fits-all solution. By combining treatment with regular monitoring and follow-up, you and your clinician can work together to achieve the best possible outcomes while managing your long-term condition.
Future Research Directions
Future research into ritlecitinib will continue to explore important areas such as combination therapies, use in children and adolescents, long-term safety and the optimisation of dosing strategies. If you are following developments in alopecia areata treatment, these studies may help provide clearer guidance on how the therapy can be used across different patient groups.
Researchers are also working to refine personalised treatment approaches, helping clinicians understand which patients are most likely to benefit from specific therapies. As new evidence emerges, you may see treatment plans become increasingly tailored to your disease severity, medical history and individual goals.
Continued investigation will help improve the long-term management of alopecia areata and expand understanding of targeted treatments. For you, this means future advances may lead to more effective, safer and more personalised options for controlling this chronic autoimmune condition.
Summary of Clinical Significance
The THRIVE-AA trials provided evidence that ritlecitinib may be an effective and generally well-tolerated oral treatment option for adults with severe alopecia areata. If you are exploring newer therapies, these studies provide valuable evidence showing how targeted treatments can help address the underlying immune processes involved in hair loss.
The trials demonstrated meaningful and sustained hair regrowth, along with improvements in quality of life for many participants. If alopecia areata has affected your confidence, appearance or daily life, these findings highlight how effective treatment may provide benefits beyond physical hair recovery.
Overall, the THRIVE-AA programme represents an important advancement in the management of alopecia areata. The evidence supports the integration of ritlecitinib into modern treatment strategies, giving you and your clinician another targeted option to consider as part of a personalised care plan.
Patient Empowerment and Monitoring
Being actively involved in your treatment decisions can help you feel more confident when managing alopecia areata. If you are taking ritlecitinib, understanding how the treatment works, what results to expect and when to seek advice allows you to play an important role in your care.
Regular follow-up appointments help your clinician monitor your progress and identify any changes early, including possible flares or side effects. By attending these reviews and sharing any concerns you have, you can help your healthcare team make adjustments that keep your treatment effective and safe.
Education, monitoring and ongoing support are all important parts of long-term management. When you work closely with your clinician and stay engaged with your treatment plan, you can maximise the potential benefits of therapy and maintain better control of your condition over time.
Key Takeaways
- The THRIVE-AA trials evaluated ritlecitinib in adults with severe alopecia areata.
- Clinical studies showed improved scalp hair regrowth compared with placebo.
- Treatment decisions should consider effectiveness, safety monitoring and individual health factors.
- Ritlecitinib represents one option within personalised alopecia areata management.
FAQs:
1. What was the THRIVE-AA trial?
The THRIVE-AA programme was a Phase III clinical trial that evaluated ritlecitinib as an oral treatment for adults with severe alopecia areata. The study assessed its effectiveness in promoting hair regrowth while monitoring its safety and tolerability.
2. What is ritlecitinib and how does it work?
Ritlecitinib is an oral medication that selectively inhibits JAK3 and TEC family kinases. It works by reducing the immune response that attacks hair follicles in alopecia areata, allowing hair to regrow.
3. Who was eligible to participate in the THRIVE-AA trials?
The trials included adults with severe alopecia areata, typically defined as having at least 50% scalp hair loss. Many participants had longstanding disease and had previously tried other treatments without satisfactory results.
4. How effective was ritlecitinib in the THRIVE-AA studies?
The trials showed that ritlecitinib achieved higher rates of meaningful scalp hair regrowth compared with placebo in adults with severe alopecia areata. Many participants also experienced improvements in eyebrow and eyelash hair growth, along with better quality of life.
5. How long does ritlecitinib take to show results?
Some participants began to notice visible hair regrowth within 8 to 12 weeks of starting treatment. However, individual responses vary, and more substantial improvements may take several months.
6. What side effects were reported during the THRIVE-AA trials?
Most side effects were mild to moderate and included conditions such as headache and nasopharyngitis. Serious adverse events were uncommon, and most participants completed treatment without significant complications.
7. Is regular monitoring required while taking ritlecitinib?
Yes. Regular blood tests are generally recommended to monitor blood cell counts and liver function during treatment. Routine follow-up appointments also help assess treatment response and overall safety.
8. Can ritlecitinib be used with other alopecia areata treatments?
In some cases, ritlecitinib may be used alongside topical treatments or other supportive therapies. Any combination treatment should be planned and monitored by a dermatologist to ensure it is appropriate and safe.
9. Does ritlecitinib improve quality of life as well as hair growth?
Yes. The THRIVE-AA trials found that many participants reported increased confidence, improved self-esteem, and better daily functioning alongside successful hair regrowth, highlighting the broader benefits of treatment.
10. What do the THRIVE-AA trials mean for the future of alopecia areata treatment?
The THRIVE-AA trials provide strong evidence that ritlecitinib is an effective oral treatment option for severe alopecia areata. The findings support its consideration as one treatment option within modern management strategies.
Final Thoughts: What the THRIVE-AA Trials Mean for Patients
The THRIVE-AA trials represent an important step forward in the treatment of severe alopecia areata, demonstrating that targeted therapies such as ritlecitinib may provide meaningful and sustained hair regrowth benefits for some patients. As research continues to refine treatment strategies, personalised care, regular monitoring, and realistic expectations remain essential for achieving the best possible outcomes.
If you are considering expert Alopecia treatment in London, you can get in touch with us at London Dermatology Centre. Our experienced dermatologists provide personalised assessments and evidence-based treatment plans tailored to your individual needs.
References:
- King, B. et al. (2023) ‘Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial’, The Lancet, 401(10387), pp.1518–1529. Available at: https://pubmed.ncbi.nlm.nih.gov/37062298/
- Alfahl, S.O.A., et al. (2025) ‘Efficacy and safety of ritlecitinib for alopecia areata: A systematic review and meta-analysis of controlled trials’, Journal of Clinical Medicine, 14(6), 1817. Available at:
https://www.mdpi.com/2077-0383/14/6/1817 - Piliang, M., et al. (2025) ‘Sustained hair regrowth with continued ritlecitinib treatment in patients with alopecia areata: A post hoc analysis of ALLEGRO-2b/3’, Journal of the American Academy of Dermatology. Available at:
https://www.sciencedirect.com/science/article/pii/S0190962224030068 - Sinclair, R., et al. (2024) ‘Patient-reported satisfaction with hair regrowth in a study of ritlecitinib for alopecia areata’, Dermatology and Therapy. Available at:
https://pmc.ncbi.nlm.nih.gov/articles/PMC11651339/ - Sinclair, R. et al. (2024) ‘Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3’, Dermatology, 240(5–6), pp.767–777. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11651339/